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Abstract
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Abnormal phosphorylation of the microtubule-associated protein tau is observed in many
neurodegenerative diseases, including Alzheimer’s disease (AD). AD-related phosphorylation of
two tau residues, Ser262 and Ser356, by PAR-1/MARK stabilizes tau in the initial phase of
mismetabolism, leading to subsequent phosphorylation events, accumulation, and toxicity.
However, the relative contribution of phosphorylation at each of these sites to tau stabilization has
not yet been elucidated. In a Drosophila model of human tau toxicity, we found that tau was
phosphorylated at Ser262, but not at Ser356, and that blocking Ser262 phosphorylation decreased
total tau levels. By contrast, when PAR-1 was co-overexpressed with tau, tau was
hyperphosphorylated at both Ser262 and Ser356. Under these conditions, the protein levels of tau
were significantly elevated, and prevention of tau phosphorylation at both residues was necessary
to completely suppress this elevation. These results suggest that tau phosphorylation at Ser262
plays the predominant role in tau stabilization when PAR-1/MARK activity is normal, whereas
Ser356 phosphorylation begins to contribute to this process when PAR-1/MARK activity is
abnormally elevated, as in diseased brains.
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INTRODUCTION
Tau is a microtubule-associated protein predominantly localized in axons, where it regulates
microtubule stability. However, in the brains of patients suffering from disorders such as
Alzheimer’s disease (AD), frontotemporal dementia with parkinsonism associated with
chromosome 17 (FTDP-17), progressive supranuclear palsy, corticobasal degeneration, and
chronic traumatic encephalopathy, tau is detached from microtubules and accumulates in the
cytosol to form neurofibrillary tangles. Several lines of evidence suggest that tau misfolding
and accumulation is the common molecular mechanism underlying the pathogenesis of
tauopathies [1].
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Tau is phosphorylated at more than 45 sites in paired helical filaments (PHF) [2–5], and
phosphorylation of specific sites plays critical roles in regulating the protein’s aggregation
and neurotoxicity [6–8]. Ser262 and Ser356 are located in the KXGS motifs in the first and
fourth microtubule-binding repeats, respectively. Tau phosphorylated at these sites is the
epitope of antibody 12E8, an established marker for tau pathology in the early stages of AD
[9, 10]. Ser262 and Ser356 are phosphorylated by PAR-1/MARK1-4 [11], a widely
conserved family of kinases [12, 13].
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PAR-1/MARK activity is elevated in several neurodegenerative conditions, including AD
[14–17]. In vitro studies have shown that phosphorylation of tau by PAR-1/MARK causes
detachment of tau from microtubules [18]. In cultured neurons, PAR-1/MARK
phosphorylation can induce mislocalization of tau from the axon to dendrite [19, 20], an
early marker of tau abnormality under disease conditions. Tau phosphorylation at Ser262
and Ser356 due to MARK overexpression increases tau toxicity, whereas preventing tau
phosphorylation at these residues by introducing unphosphorylatable alanine substitutions
reduces tau toxicity in cellular and Drosophila models [8, 13, 21]. Moreover, tau toxicity is
elevated under pathological conditions such as β-amyloid accumulation and mitochondrial
dysfunction [22–26], and increases in PAR-1/MARK activity, as well as the level of tau
phosphorylated at Ser262 and Ser356, correlate with tau toxicity [24, 25, 27]. Recently, we
showed in a Drosophila model that tau phosphorylation at Ser262 and Ser356 by PAR-1
stabilizes tau at the initial step of mismetabolism, thereby promoting tau toxicity [28].
However, the relative contribution of tau phosphorylation at each of these sites to tau
stabilization remained unclear.

Author Manuscript

In this study, we sought to investigate how Ser262 and Ser356 contribute individually to
stabilization of tau when PAR-1/MARK activity is normal or abnormally elevated. Using a
Drosophila model of tau toxicity [25, 29], we found that tau phosphorylation at Ser262 plays
a predominant role in tau stabilization. Tau phosphorylation at Ser356 was not detectable
under normal conditions; however, when PAR-1 was overexpressed, tau was phosphorylated
at Ser356, and this phosphorylation contributed to tau stabilization. These results suggest
that tau phosphorylation at Ser356 plays a role in stabilizing tau under pathological
conditions in which PAR-1 activity is very high.
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MATERIALS AND METHODS
Fly stocks
Flies were maintained in standard cornmeal media at 25 ºC. The transgenic fly lines carrying
the human 0N4R tau, which has four tubulin-binding domains (R) at the C-terminal region
and no N-terminal insert (N), include a gift from Dr. M. B. Feany (Harvard Medical School)
[29] and the lines established in our labs following the standard method [27, 30] by using
human 0N4R tau (a gift from Dr. Mike Hutton (Mayo Clinic Jacksonville)). The transgenic
fly line carrying UAS-S262Atau and UAS-S2Atau are established in our labs and reported
previously [27, 28, 30]. GMR-GAL4 was obtained from the Bloomington Stock Center.
UAS-PAR-1 is a gift from Dr. Bingwei Lu (Stanford University) [31]. All experiments were
performed using female flies at 3–5 day-old after eclosion. Genotypes are described in Table
S1.
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Western blotting
Western blotting was carried out as described previously [27, 28]. Multiple membranes were
prepared with the same samples, and one of the membranes was probed with anti-tubulin
and used as the loading control for other blots. Anti-tau monoclonal antibody (Tau46,
Zymed), anti-tau phospho-Ser262 (AbCam), phospho-Ser356 (Biosource), TAU1
(Millipore), and anti-tubulin (Sigma) were purchased. Anti-tau pS202 (CP13) was a gift
from Dr. Peter Davis (Albert Einstein College of Medicine, USA), and anti-tau polyclonal
antibody (tauC) was a gift from Dr. A. Takashima (Gakushuin University, Japan) [32]. The
signal intensity was quantified using ImageJ (NIH). Western blots were repeated a minimum
of three times with different animals.
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Phosphatase treatment
As described previously [28], twenty fly heads were homogenized in NEBuffer1 for PMP
(50 mM HEPES, 100 mM NaCl, 2 mM DTT, 0.01% Brij 35, pH 7.5) supplemented with 1
mM MnCl2 (NEB) and 0.4 mM 4-(2-aminoethl)-benzenesulfonyl fluoride hydrochloride
(Pefabloc) (Wako Chemicals), 10 μg/ml leupeptin (Peptide Institute), and incubated with λ
protein phosphatase (NEB) for 3h at 37°C.
RNA extraction and quantitative real-time PCR analysis
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Heads from more than thirty flies were mechanically isolated, and total RNA was extracted
using ISOGEN (NipponGene) followed by reverse-transcription using PrimeScript RT
reagent kit (Takara). The resulting cDNA was used as a template for PCR with
THUNDERBIRD SYBR qPCR mix (TOYOBO) on a Thermal Cycler Dice real time system
TP800 (Takara). Expression of genes of interest was standardized relative to rp49. Relative
expression values were determined by the deltaCt method.
Primers were;
htau for 5′-CAAGACAGACCACGGGGCGG-3′
htau rev 5′-CTGCTTGGCCAGGGAGGCAG-3′
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rp49 for 5′-GCTAAGCTGTCGCACAAATG-3′
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rp49 rev 5′-GTTCGATCCGTAACCGATGT-3′
Statistics
Statistics was done with Microsoft Excel (Microsoft) with Student's t.

RESULTS
Tau phosphorylation at Ser262 is critical for stabilization of tau in a Drosophila model of
human tau toxicity
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Wild-type human 0N4R tau proteins expressed in the fly retina under the control of the eyespecific GMR-Gal4 driver were detected as two major bands by western blotting with pantau antibody (Figure 1, total tau). The difference in migration speed between these two
bands is related to their phosphorylation levels: tau in the slower-migrating band (tauupper) is
more highly phosphorylated than tau in the faster-migrating band (taulower) [28]. In addition,
taulower can be distinguished by TAU-1 antibody (TAU-1-positive tau) [28], which
recognizes tau that is non-phosphorylated at the AD-related sites Ser195, 198, 199 and
Ser202 [33]. The levels of taulower and TAU-1-positive tau are prominently decreased by
introduction of S262A/S356A double mutation (S2A) or knockdown of PAR-1, the major
kinase that phosphorylates tau at both sites [28].
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Wild-type human 0N4R tau overexpressed in fly retina was phosphorylated at Ser262 ([8,
13, 21, 25] and Figure 1, pS262), whereas phosphorylation at Ser356 was not detectable
(Figure 1, pS356). However, Ser356 was strongly phosphorylated when PAR-1 was coexpressed (Figure 3A), confirming that the antibody used in this study can recognize tau
phosphorylated at this residue. These results suggest that tau phosphorylation levels at
Ser356 are very low in fly retina.
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To investigate the role of Ser262 in stabilization of tau, wild-type human 0N4R tau or tau in
which Ser262 was replaced with unphosphorylatable alanine (S262A) was expressed in the
fly retina. qRT-PCR analysis revealed that mRNA levels of S262A tau were higher than
those of wild-type tau (Figure 2A). However, western blotting revealed that S262A tau was
significantly less abundant than wild-type tau (Figure 2B, quantitation, top, total tau).
Interestingly, in contrast to wild-type tau, S262A tau exhibited a major band corresponding
to tauupper (Figure 2B, total tau, tauupper). The signal intensities of taulower normalized to
total tau was significantly lower for S262A tau than for wild-type tau (Figure 2B,
quantitation, middle, taulower), whereas that of tauupper was not significantly different
(Figure 2B, quantitation, middle, tauupper ). Moreover, western blotting with TAU-1
antibody, which only detects taulower [28], revealed that the level of TAU-1-positive tau
normalized to total tau was significantly lower for S262A tau than for wild-type tau (Figure
2B, TAU-1; also see quantitation, bottom, TAU-1). Because taulower or TAU-1 tau represents
less phosphorylated forms of tau, S262A mutation might reduce the levels of taulower or
TAU-1-positive tau by promoting tau phosphorylation. However, this was not the case: the
levels of tau phosphorylated at Ser202 normalized to total tau were also significantly lower
in S262A tau than in wild-type tau (Figure 2B, pSer202; also see quantitation, bottom,
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pSer202). Taken together, these results indicate that Ser262 phosphorylation plays a major
role in stabilizing tau, especially the less extensively phosphorylated forms.
Tau phosphorylation at Ser356 contributes to stabilization of tau when PAR-1 activity is
abnormally elevated
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Phosphorylation at Ser356 was not detectable normally (Figure 1); accordingly, it is unlikely
to play a major role in stabilizing tau [28]. However, tau was phosphorylated at Ser356 when
PAR-1 was overexpressed (Figure 3A) [28], suggesting that Ser356 contributes to
stabilization of tau when PAR-1 activity is abnormally elevated. Therefore, we asked
whether blocking tau phosphorylation at Ser262 would be sufficient to suppress the increase
in tau levels caused by co-expression of PAR-1 (Figure 3A). To this end, we analyzed tau
levels by western blotting with a pan-tau antibody. To rule out the possibility that changes in
tau phosphorylation affect the affinity of a pan-tau antibody, lysates used for quantitation
were treated with phosphatase prior to western blotting. We found that introduction of the
Ser262Ala mutation alone partially, but not completely, suppressed increases in tau levels
(Compare Figure 3A and B). Because co-expression of PAR-1 significantly increased
phosphorylation levels of S262Atau at Ser356 (Figure 3B, pSer356), Ser356
phosphorylation may contribute to tau stabilization under this condition. Consistent with this
idea, introduction of alanine mutations at both Ser262 and Ser356 (S2A) completely blocked
the increase in tau levels caused by PAR-1 overexpression (Figure 3C and [28]). These
results suggest that tau phosphorylation at both Ser262 and Ser356 contributes to
stabilization of tau under conditions in which PAR-1 activity is very high.

DISCUSSION
Author Manuscript
Author Manuscript

Multiple residues in tau are phosphorylated in brains of tauopathy patients, but the roles of
each site in disease pathogenesis remain incompletely understood. Ser262 and Ser356 are
both disease-specific phosphorylation sites [2] and have been implicated in structure,
turnover, intracellular distribution, and promotion of tau toxicity in disease pathogenesis [8,
13, 18–27]. In this study, we investigated the effect of Ser262 and Ser356 on the stabilization
of various tau species and the accumulation of tau caused by PAR-1 overexpression. Our
results revealed that phosphorylation at Ser262 plays the predominant role in the
stabilization of TAU-1-positive, less extensively phosphorylated forms of tau (Figures 1 and
2). This observation is consistent with a previous report that introduction of a single
substitution of Ser262 to unphosphorylatable alanine is sufficient to suppress
neurodegeneration caused by tau overexpression in the Drosophila model [25]. By contrast,
Ser356 phosphorylation was only detectable when PAR-1 was overexpressed, suggesting
that phosphorylation at this residue contributes additively to tau stabilization under this
condition in our Drosophila model (Figure 3). Together, these results suggest that tau
phosphorylated at Ser356 is associated with abnormal tau metabolism and represents a more
advanced stage of tau pathology than tau phosphorylated at Ser262 (summarized in Figure
4).
PAR-1/MARK activity is elevated in several pathological contexts, including AD [14–17].
MARK4 is co-expressed with tau phosphorylated at Ser262 in a Braak stage-dependent
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manner [14]. The level of active MARKs is increased by β-amyloid, which is thought to be
the primary causative agent of AD pathology and to act upstream of tau toxicity [23, 24, 34].
The level of active MARKs is also increased by mitochondrial abnormality [35], stimulation
of NMDA receptor [36], and ischemic events [37], all of which also promote pathological
changes in tau. High MARK activity is associated with AD risk factors such as obesity:
MARKs regulate the metabolic rate, and MARK activity is elevated in animals with dietinduced obesity [38, 39]. These reports suggest that neurons in AD brains have higher levels
of active MARKs than those in normal brain, and tau is stabilized more often by Ser356
phosphorylation. In addition to MARK, tau phosphorylation at Ser356 is regulated by
several kinases, including AMPK, AKAP14, DYRK1A, S6K, and PKA, phosphorylase
kinase, and PKR [22, 40–43]. Disruption of the regulatory mechanisms of these kinases
and/or phosphatases may also contribute to the stabilization of abnormal tau in disease
neurons.
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How does tau phosphorylation at Ser262 and Ser356 stabilize tau proteins? Ser262 and
Ser356 are located in KXGS motifs in the first and fourth microtubule-binding repeat
domains, respectively. In addition to directly binding microtubule [44], the microtubulebinding domain affect the structure, metabolism, and intracellular distribution of tau [18–20,
45–48]. Interestingly, the microtubule-binding domain is also critical for self-association of
tau [49]. Because both the binding of tau to microtubules and its self-association/aggregation
could affect its stability, tau phosphorylation at both Ser262 and Ser356 is expected to affect
these processes [18, 20, 22, 28, 45, 50].
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In brains of tauopathy patients, tau exists in multiple forms associated with distinct
modifications, binding partners, and/or cellular locations, and its toxicity is likely to be
qualitatively and quantitatively heterogeneous [51]. Therefore, targeting tau species in the
initial phase of abnormal metabolism represents a promising therapeutic strategy. This study
underscores the importance of tau phosphorylation at Ser356 in stabilizing tau when PAR-1/
MARK activity is abnormally elevated. Further study of the mechanisms underlying
dysregulation of Ser262 and Ser356 phosphorylation, as well as the molecular mechanisms
underlying tau stabilization, will identify therapeutic strategies to delay onset and
progression of tauopathies.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
•

Ser262, but not Ser356, is phosphorylated in tau overexpressed in fly eyes.

•

Ser262 phosphorylation plays a predominant role in tau stability.

•

Tau phosphorylation at Ser356 occurs when PAR-1 is co-overexpressed.

•

Tau phosphorylation at Ser356 stabilizes tau when PAR-1 activity is high.
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Figure 1. Wild-type human 0N4R tau overexpressed in fly retina is phosphorylated at Ser262,
but not Ser356
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Western blot analysis of fly heads carrying the eye-specific GMR-Gal4 driver alone
(negative control) or expressing human tau driven by GMR-Gal4 (tau) with a pan-tau
antibody (total tau) or antibodies that recognize the phosphorylation status of tau at specific
sites (pSer262 and pSer356). Tau in the slower-migrating band (tauupper) and the fastermigrating band (taulower) are indicated. The asterisk indicates a non-specific band detected
by pSer356 antibody in the negative control. Tubulin was used as a loading control.
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Figure 2. Blocking tau phosphorylation at Ser262 with unphosphorylatable alanine substitutions
(S262A) preferentially reduces the levels of less extensively phosphorylated forms of tau
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(A) Tau mRNA levels in fly heads expressing human wild-type tau (tau) and S262A tau
(S262A) were quantitated by qRT-PCR (means ± SD, n = 3; *p<0.05, Student's t-test). (B)
Introduction of the S262A mutation decreased the levels of tau, with a more pronounced
effect on taulower. Western blotting of wild-type tau or S262Atau with pan-tau antibody
(total tau) or antibodies that recognize the phosphorylation status of tau at specific sites
(TAU-1 and pS202). Representative blot (left), relative ratio of signal intensities of total tau
(right, top), the relative ratio of signal intensities of tauupper and taulower (right, middle), and
relative ratio of signal intensities of TAU-1 and pS202 (right, bottom) are shown. Means ±
SD, n = 5; *, p < 0.05; ***, p < 0.005, n.s., not significant by Student's t-test. Tubulin was
used as a loading control.
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Figure 3. Tau phosphorylation at Ser356 contributes to stabilization of tau when PAR-1 activity
is abnormally elevated
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(A) Western blot of fly heads expressing tau (tau) or co-expressing tau and PAR-1 (tau
+PAR-1), with or without phosphatase treatment, with anti-pan-tau antibody (tau) or an
antibody that recognizes tau phosphorylated at Ser356 (pS356). The asterisk indicates a nonspecific band detected by the anti-pSer356 antibody after phosphatase treatment. (B)
Western blot analyses of fly heads expressing S262A tau (S262A) or co-expressing S262A
and PAR-1 (S262A+PAR-1) with anti-tau antibody (tau) or anti-pSer356 antibody (pS356).
(C) Western blot of fly heads expressing tau carrying the S262A/S356A double mutation
(S2A) or co-expressing S2A and PAR-1 (S2A+PAR-1), with anti-tau antibody (tau).
Representative blots are shown, along with the relative ratios of signal intensities of total tau
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blots of phosphatase-treated samples. Means ± SD, n = 4–5; ***, p < 0.005 by Student's ttest. Tubulin was used as a loading control.
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Figure 4. Working model of the roles of Ser262 and Ser356 in tau stabilization

(Left) When PAR-1/MARK activity is normal, tau phosphorylation at Ser262 plays the
predominant role in the stabilization of tau. (Right) By contrast, when PAR-1/MARK
activity is high, tau phosphorylation at Ser356 occurs and contributes additively to tau
stabilization. This process promotes subsequent tau phosphorylation, accumulation and
toxicity.
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